NCT04701788View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Immunogenicity and Safety of PPV23 Vaccine Revaccinations in the Elderly

PHASE4CompletedINTERVENTIONAL
Enrollment

331

Participants

Timeline

Start Date

March 30, 2021

Primary Completion Date

December 20, 2021

Study Completion Date

February 15, 2022

Conditions
Vaccination
Interventions
BIOLOGICAL

23-valent pneumococcal polysaccharide vaccine

The study group and the control group were injected with a dose of 23-valent pneumococcal polysaccharide vaccine. One month later, blood was collected and serum was separated.

Trial Locations (1)

610041

Sichuan Center for Disease Control and Prevention, Chengdu

All Listed Sponsors
collaborator

Sichuan Center for Disease Control and Prevention

OTHER_GOV

lead

China National Biotec Group Company Limited

INDUSTRY

NCT04701788 - A Clinical Trial to Evaluate the Immunogenicity and Safety of PPV23 Vaccine Revaccinations in the Elderly | Biotech Hunter | Biotech Hunter